ClinicaliQ Trial Snapshot
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients — Recruiting • Phase III • Oncology • NCT06549595.
- What is being tested: Surovatamig (AZD0486), a novel agent, combined with rituximab versus standard immunochemotherapy regimens (investigator's choice of 3 options) in treatment-naive follicular lymphoma patients, evaluating efficacy, safety, and added clinical benefit.
- Patient eligibility overview: Previously untreated adult patients with follicular lymphoma who are candidates for systemic therapy, enrolled across multiple global centres in a randomised Phase III design.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
Eligibility Snapshot
- :
- Participant must be at least 18 years of age, inclusive, at the time of signing the ICF. 2. Histologically confirmed diagnosis of classic FL per WHO 2022 classification 3. ECOG performance status of 0 to 2 4. No prior systemic lymphoma-directed therapy 5. Need for systemic treatment meeting at least 1 GELF criteria 6. FDG-avid and measurable disease 7. Stage II to IV and FLIPI 2-5 [Phase III only] 8. Adequate liver, hematological, renal and cardiac function. The above is a summary, other inclusion criteria details may apply
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.